Ecabet

Drug Profile

Ecabet

Alternative Names: Gastrom; TA 2711; TA 2711E

Latest Information Update: 11 Aug 2015

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Developer Boehringer Ingelheim; ISTA Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Senju Pharmaceutical
  • Class Antiulcers; Phenanthrenes; Small molecules
  • Mechanism of Action Prostaglandin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric ulcer; Gastritis
  • Discontinued Dry eyes; Gastrointestinal disorders; Ulcerative colitis

Most Recent Events

  • 06 Jun 2012 ISTA Pharmaceuticals has been acquired by Bausch & Lomb
  • 22 Jan 2009 Efficacy data from a phase IIb trial in Dry eyes released by ISTA Pharmaceuticals
  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top